New Diagnostics Working Group Guidelines & Policies

WHO Guidlines & Policy

Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children (2013) Updated policy statement
Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children Expert Group meeting report
Automated real- time NAAT for Tuberculosis and Rifampicin Resistance (2011) Policy statement

Molecular Line Probe Assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (first-line LPAs) (2008) Policy statement
The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs Expert Group meeting report

The use of liquid medium for culture and DST (2007) Policy
Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs (2008) Policy
Updated critical concentrations for first-line and second-line DST (May 2012)
Non-commercial culture and drug susceptibility testing methods for screening patients at risk of multidrug-resistant tuberculosis (2011) Policy statement
Expert Group meeting report: Non-commercial culture methods and mycobacteriophage-based assays Expert Group meeting report

Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis (2010) Policy statement
Same-day diagnosis of tuberculosis by microscopy (2010) Policy statement
Approaches to improve smear microscopy for TB diagnosis Expert Group meeting report
Definition of a new sputum smear-positive TB case (2007) Policy
Reduction of number of smears for the diagnosis of TB Policy

Use of TB IGRAs in low- and middle-income countries (2011) Policy statement
Use of Interferon-y Release assays (IGRAs) in tuberculosis control in low- and middle-income settings Expert Group meeting report

Commercial serodiagnostic tests for diagnosis of tuberculosis (2011) Policy statement
Commercial serodiagnostic tests for diagnosis of tuberculosis Expert Group meeting report